Drug intelligence / Profile preview

BCM-0252

Development stage: Preclinical
Lead developer: Biocidium Biopharmaceuticals
Modality: Small Molecules
Administration: Oral, Topical

Overview

BCM-0252 is a chemical drug candidate developed by Biocidium Biopharmaceuticals for the treatment of infectious diseases, with a primary focus on multi-drug resistant *Shigella* (*Shigella* – DR). It is being formulated for both oral and topical administration. The drug is currently in preclinical development and targets indications such as bacillary dysentery, which is caused by *Shigella* infection. Its mechanism of action has not been publicly disclosed. The developer, Biocidium Biopharmaceuticals, specializes in therapies targeting antimicrobial resistance.

Beyond the preview

Go deeper on BCM-0252.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCM-0252.

Explore the full profile